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Abstract
Background: Inflammatory bowel disease (IBD) is characterized by chronic or relapsing immune system activation
and inflammation within the gastrointestinal tract. The lack of safety and efficacy of standard therapies, the use of
food supplements for managing IBD is increasing, and many studies have reported that various food supplements
provide many beneficial effects for the IBD.
Methods: This study aimed to evaluate the anti-colitis effects of dietary supplementation with a fermented barley
and soybean mixture (BS) on intestinal inflammation using a murine model of IBD. Female C57BL/6 mice were
administered with either BS (100 and 200 mg/kg/day) or vehicle (PBS) control through oral gavages for 3 days and
received 5% dextran sulfate sodium (DSS) drinking water to induce colitis. Mice body weight was measured every
two days and disease activity index (DAI) score was determined on Day 15; mice were sacrificed and colons were
analyzed by H & E staining and RT-PCR. We also measured intestinal barrier function in vitro using DSS-treated
Caco-2 cells by assessing ZO-1 immunofluorescence staining and Western blotting and in vivo by measuring serum
level of FITC-Dextran and by performing bacteria culture from mesenteric lymph nodes (MLN) extract. The gut
microbiota was examined by real time PCR using fecal DNA.
Results: We found that BS alleviated the severity of colitis in a DSS-induced colitis mouse model, and suppressed
levels of pro-inflammatory cytokines in colonic tissue. Moreover, BS prevented epithelial barrier dysfunction,
inducing an increase of tight junction protein levels in colonic tissues, BS also inhibited FITC-dextran permeability,
and suppressed bacterial translocation to MLNs. In addition, BS increased the levels of Lactobacilli and Bacteroides,
which have anti-inflammatory properties.
Conclusion: Our study suggests that BS has protective roles against inflammatory bowel disease through changes
in inflammatory activity, tight junction protein expression, and gut microbiota composition in DSS-induced colitis.
Keywords: Dietary supplementation, Fermented foods, Intestinal bowel disease, Intestinal microbiota, Food
supplements, Inflammatory bowel disease
* Correspondence: eyeball@hanmail.net; eyeball@gachon.ac.kr
1Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon
21999, Republic of Korea
5College of Pharmacy, Gachon University, 191 Hambakmoero, Yeonsu-gu,
Incheon 21999, Republic of Korea
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Woo et al. BMC Complementary and Alternative Medicine  (2016) 16:498 
DOI 10.1186/s12906-016-1479-0
Background
Inflammatory bowel disease (IBD), including Crohn’s
disease (CD) and ulcerative colitis (UC), is characterized
by chronic inflammation of the gastrointestinal tract. Al-
though the etiology of IBD remains poorly understood,
IBD pathogenesis is reportedly associated with dysfunc-
tion of the intestinal epithelial barrier and alteration of
intestinal microbiota [1].
Impaired epithelial barrier results in increased intes-
tinal permeability to harmful bacteria and other anti-
gens, leading to chronic immune response. Indeed,
increased intestinal permeability is reported in IBD pa-
tients [2]. This indicates that dysfunction of epithelial
barrier is likely an initial event before onset or recur-
rence of IBD.
Intestinal epithelial permeability is regulated by
tight junction complex [3]. Several studies have ob-
served structural abnormalities in tight junction com-
plexes, including down-regulation of ZO-1, Occludin
and Claudin-1, in IBD patients as a cause of altered
intestinal permeability [4]. Therefore, modulation of
intestinal permeability is a highly regarded target for
novel therapeutic treatment against IBD.
In addition to alterations in tight junction complex in-
tegrity, gut microbiota is critical players in intestinal
permeability. An imbalance between beneficial and
pathogenic bacteria is involved in IBD pathogenesis [1].
Soybeans (Glycine max) are good sources of isoflavo-
noids (genistein and daidzein), which are bioactive com-
ponents that have beneficial activity on health. They are
known for anti-inflammatory, anti-cardiovascular, and
anti-obesity activities [5]. Barley (Hordeum vulgare) is a
major part of the diet as cereal. B-glucan, an active con-
stituent of barley, has been reported to show anti-
inflammatory and anti-cancer effects [6]. In our previous
study, we developed a fermented barley and soybean
mixture (BS) that increased production of β-glucan and
isoflavonoids (genistein and daidzein). We showed that
BS components produced significant protective effects
against UVB-induced photoaging. Until now, it has been
no report about the protective activity of BS on intes-
tinal barrier function. In this study, we investigated
whether BS protects the epithelial barrier and, if so,
whether changes in tight junction protein expression
and composition of microflora contribute to this effect.
To answer these questions, mice with DSS-induced col-
itis were treated with BS, and epithelial permeability,




DSS (MW 36–50 kDa) was purchased from MP Biomed-
icals LLC (Santa Ana, CA, USA). DMEM, fetal bovine
serum (FBS), penicillin (100 unit/mL) and streptomycin
(100 μg/mL) were obtained from Welgene, Inc. (Daegu,
Korea). The following antibodies were used in these
studies: anti-ZO-1, anti-Occludin, anti-Claudin-1, IL-6
(Thermo Scientific, Grand Island, NY, USA), and
GAPDH (Santa Cruz, CA, USA). Fermented barley and
soybean (BS) were obtained from Sempio Fermentation
Research Center (Osong, Korea). Barley (Hordeum vul-
gare) was cultivated by the agricultural Technology
Center of Yeonggwang-gun, Jeollanam-do, and Republic
of Korea. Soybean (Glycine max (L.) MERR) was sup-
plied by Sempio Foods Company (Seoul, Korea). Vou-
cher specimens were deposited in the herbarium at the
R&D Center of Sempio Foods Company. Briefly, fermen-
tation was performed using enzymatically hydrolyzed
barley (40 g/L) and soybean (40 g/L) mediums. The
medium was autoclaved and pH was adjusted to 7.0 with
2 M ammonia solution. The pre-cultured yeast, P. jadinii
(KFCC 11487P), was inoculated into the enzymatically
hydrolyzed barley and soybean. Fermentation was re-
spectively conducted at 30 °C with shaking at 20 × g for
48 h in a 5 L bioreactor, and samples were dried and
stored at −18 °C [7]. BS powder was dissolved in phos-
phate buffered saline (PBS) and then was stored at −20 °C.
In vitro DSS treatment
Human colon carcinoma cell line (Caco-2) was ob-
tained from the Korea Cell Line Bank (Seoul, Korea).
Cells were grown at 37 °C in DMEM supplemented
with 10% FBS, penicillin and streptomycin in a hu-
midified atmosphere of 5% CO2. To test the effect of
BS on DSS-treated Caco-2 cells, cells were seeded
onto 12-well plates (SPL Life Science, Pocheon,
Korea). After reaching 90–100% confluency, the Caco-
2 cell monolayers were allowed to differentiate for an
additional 14 days. Fully differentiated cell monolayers
were incubated with or without 2% DSS in the ab-
sence or presence of 100, 200, and 400 μg/mL BS for
48 h. DSS was dissolved in culture media and filter-
sterilized using a 0.45-μm filter [8–10].
Immunofluorescence assay
Cells grown on glass coverslips and frozen tissues were
fixed and permeabilized in methanol or acetone at −20 °C.
Cells or tissues were incubated with primary antibodies
overnight at 4 °C, followed by incubation with FITC-
labeled secondary antibody for 1 h at room temperature.
Sections were then mounted with mounting medium con-
taining 4, 6-diamidino-2-phenylindole (DAPI) for nuclear
counterstaining. Images were observed by fluorescence
microscopy. FITC and DAPI images were taken from the
same area.
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Western blot analysis
Whole cell and detergent-insoluble fractions were pre-
pared as described previously [11]. Briefly, whole cell
protein lysates and detergent-insoluble fractions were
prepared in a modified RIPA buffer containing protein-
ase inhibitors and phosphatase inhibitors as described
elsewhere [12]. Homogenates were spin down at
12,000 rpm at 4 °C for 20 min. Supernatants were col-
lected for whole cell lysates and the pellets used as
detergent-insoluble fractions. The pellets were dissolved
in 0.1% SDS. Protein concentration of each samples was
determined using BCA reagents (Thermo Scientific).
Equivalent amounts of protein (20–80 μg) were loaded
in 10% or 12% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE) gels and transferred by
blotting to polyvinylidene fluoride membranes. The blot
was incubated with primary antibodies against human
ZO-1, Occludin, Claudin-1, or GAPDH. After washing,
the blot was incubated with HRP-conjugated secondary
antibodies. The protein–antibody complexes were de-
tected by Absignal (Abclone, Seoul, Korea) according to
the manufacturer’s recommended protocol.
Animal study
Six-week-old female C57BL/6 mice (weighing 20 ± 2 g)
were received from the Orient Co. (a branch of Charles
River Laboratories, Seoul, Korea). The mice were housed
in a specific pathogen free (SPF) animal facility and ac-
climated under the conditions of 22 ± 2 °C, 40–60% rela-
tive humidity, and 12 h light/dark cycle for 7 days. Mice
were divided into 4 groups of 5 mice each. The first
group was vehicle-treated control and the second group
was given drinking water with DSS only. The third and
fourth groups of mice were treated with BS (100 and
200 mg/kg/day) through oral gavage for 3 days, then ex-
posed to 5% DSS in their drinking water for 7 days to in-
duce colitis. After DSS treatment, BS treatment groups
were additionally administered BS for 4 days according
to the experimental design. The study used the animal
model to study the effects of fermented barley and soy-
bean mixture during inflammation.
In vivo permeability assay
In vivo permeability assay was performed to assess bar-
rier function using fluorescein isothiocyanate dextran
(FITC-D). For each experiment, mice were divided into
4 groups of 5 mice each. The first group was vehicle-
treated control and the second group was given drinking
water with DSS only. The third and fourth groups of
mice were treated with BS (100 and 200 mg/kg/day)
through oral gavage for 3 days, then exposed to 5% DSS
in their drinking water for 7 days to induce colitis.
Briefly, food and water were withdrawn for 4 h, and
mice were inoculated with FITC-D by oral gavage
(20 mg/kg). After 4 h, mice serum was collected and
fluorescence intensity was measured (excitation, 492 nm;
emission, 525 nm). Detection of viable bacteria in mes-
enteric lymph nodes (MLNs) represented bacterial trans-
location from the lumen to the MLNs. The MLNs of left
colonic regions were removed aseptically and were put
into eppendorf tubes with 0.1-mL sterilized PBS and tis-
sues were homogenized by micro grinder (RPI, Mount
Prospect, IL, USA). The homogenates were plated on
blood agar (Thermo Fisher Scientific, Lenexa, KS, USA)
and incubated for 48 h at 37 °C. The number of colonie
was counted and the ratio of bacterial translocation was
presented for percentages.
Semi-quantitative RT-PCR and quantitative PCR (qPCR)
with 16S rRNA for specific species
For semi-quantitative RT-PCR, 1 μg of RNA was used as
a template for reverse-transcription using the Prime
Script 1’st strand cDNA Synthesis kit (Takara; Kyoto,
Japan). PCR was carried out with 20 ng of cDNA using a
PCR pre-mixture (Takara). RT-PCR was performed to
amplify genes using a cDNA template corresponding to
gene-specific primer sets. The primer sequences used
are as follows. Primer sequences are listed in the
Additional file 1: Table S1. Fecal samples were collected
before necropsy and immediately frozen in liquid nitro-
gen. Bacterial genomic DNA was extracted from fecal
samples using a Wizard genomic DNA purification kit
(Promega, Madison, WI, USA) according to the manu-
facturer’s instructions. The abundance of specific intes-
tinal bacterial groups was measured by qPCR. Genus- or
species-specific 16S rRNA gene primers were used as
described previously [13]. Primer sequences are listed in
the Additional file 1: Table S2. 16S rRNA of Eubacteria
was used as a housekeeping gene.
Statistical analysis
The results are analyzed by one-way analysis of variance
(ANOVA) and differences were considered statistically
significant at level of p-values < 0.05.
Results
The effect of BS on the structure of tight junction
complexes in vitro
Since Caco-2 is an intestinal epithelial cell line and
forms a monolayer when cultured to 100% confluence, it
is broadly used as a model of the intestinal barrier [14].
To study the protective efficacy of BS in the epithelial
barrier, the Caco-2 cell line was used. When the cells
were incubated with DSS, the expression of tight junc-
tion proteins such as ZO-1, and caludin-1 was de-
creased. BS treatment dose-dependently recovered the
loss of tight junction proteins in DSS-treated Caco-2
monolayer (Fig. 1a and b). Consistent with this,
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immunostaining with anti-ZO-1, Occludin and Claudin-
1 showed that tight junction in DSS-induced monolayer
was markedly disrupted, but treatment with BS pro-
tected tight junction complex from DSS-induced dam-
age (Fig. 1c). These data suggest that BS might
contribute maintenance of epithelial barrier integrity by
preserving tight junction proteins. However, BS single
treatment doesn’t enhanced expression of tight junction
proteins (Additional file 2: Figure S2).
BS prevents symptoms of DSS-induced colitis in mice
To evaluate the therapeutic effect of BS on DSS-induced
colitis, we investigated the ability of BS to ameliorate
DSS-induced colitis by assessing body weight, disease ac-
tivity index (DAI), and colon length and by performing
histological analysis. We found that BS (200 mg/kg)
treatment relieved the loss of body weight from day 12
to day 15, compared to the group treated with DSS only
(Fig. 2a). Following induction of colitis, the BS treatment
reduced DAI scores compared with only DSS treatment
(Fig. 2b). In addition, while colon length was decreased
in the DSS group compared with vehicle group, BS miti-
gated this shortening of colon length (Fig. 2c). Colon
tissues were histologically analyzed to evaluate DSS-
induced inflammation and epithelial damage. We found
that DSS-treated mice exhibited acute colitis with severe
inflammation and crypt damage. These changes were re-
duced by treatment with BS (Fig. 2d). In addition to
macroscopic changes, production of pro-inflammatory
cytokines is also important in the development of IBD
[15]. Therefore, we investigated the effect of BS on pro-
inflammatory cytokine production in the DSS-induced
colitis model by using RT-PCR. We found that BS
(200 mg/kg) significantly reduced DSS-induced mRNA
levels of TNF-α, IL-1β, IL-6, and IL-12p40 in colonic tis-
sues (Fig. 2e). At the same time, BS treated mouse
showed a lower level of expression of the IL-6 in the in-
flamed colon (Additional file 2: Figure S4). These results
indicate that the BS treatment diminished the severity of
DSS-induced colitis. Moreover, nutrient supplementa-
tion leads to beneficial effects in a DSS-induced colitis
model. We included LPS-induced colitis models to
confirmed therapeutic activity of BS. We included
Additional file 2: Figures S1 to demonstrate that activity
of BS on LPS-induced colitis models. We found that BS
(200 mg/kg) treatment relieved DAI scores compared
with LPS treatment (Additional file 1: Figure S1A) and
reduced LPS-mediated tissues damage (Additional file 1:
Figure S1B).
BS prevented DSS-induced disruption of tight junction
complexes and loss of tight junction proteins
To investigate the protective effect of BS against DSS-
induced disruption of tight junction, we examined the
expression and organization of tight junction proteins
including ZO-1, Occludin and Claudin-1 using immuno-
fluorescence assay and Western blotting.
Immunofluorescence assays demonstrated consider-
able loss of ZO-1, Occludin, and Claudin-1 in tight junc-
tion complexes of the DSS-treated group and structural
discontinuities in their architecture, in the inner lining
of the colonic epithelium. Interestingly, BS treatment
significantly prevented the loss of tight junction proteins,
ZO-1, Occludin, and Claudin-1 in tight junction
complexes of colonic epithelial cells (Fig. 3a).
Fig. 1 The effect of BS on the structure of tight junction complexes in vitro. (a and b) Immunoblot analysis of tight junction proteins in the
detergent-insoluble fractions. c Immunofluorescence of ZO-1, Occludin, and Claudin-1 in Caco-2 cell monolayers incubated with 2% DSS in the
absence or presence of indicated concentrations of BS for 48 h. Images were collected by confocal microscopy. Magnification x600
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To extend our observations of dramatic changes in
tight junction proteins, we conducted Western blotting
using colon tissues. Compared with the control group,
there were significant reductions in the expression of
Occludin and Claudin-1 in the DSS-treated group. In
contrast, total protein level of ZO-1 remained un-
changed. This indicates that the loss of Occludin and
Claudin-1 at colonic epithelial tight junctions of DSS-
treated mice was paralleled by quantitatively reduced
protein expression (Fig. 3b). This might indicate a redis-
tribution of existing proteins to the basolateral mem-
brane. On the other hand, expression of tight junction
proteins in BS-treated groups was significantly higher
than in the DSS-treated group (Fig. 3b), suggesting that
BS may play an important role in maintaining the integ-
rity of tight junction complexes.
BS prevented increased colonic epithelial permeability in
DSS-induced colitis
To determine the effect of BS on epithelial permeability,
we analyzed intestinal permeability in DSS-induced col-
itis model. To that end, the level of bacterial transloca-
tion was measured (Fig. 4a). Compared with control
group, a significant increase of bacterial translocation
into the MLNs was observed in the DSS-treated group.
Interestingly, the bacterial translocation was completely
prevented by administration of BS. We also measured
FITC-D permeability in order to determine if BS treat-
ment prevented disruption of epithelial barrier function
induced by DSS treatment (Fig. 4b). Mice in DSS-treated
group had elevated levels of FITC-D in serum, compared
with those in the control group. Administration of BS
reduced FITC-D serum levels compared with that in the
DSS-treated group. These results show that BS de-
creased epithelial permeability, suggesting that BS treat-
ment prevented gut leakiness to a greater extent.
BS regulated composition of fecal microflora in DSS-
induced colitis mouse model
Gut microbiota are increasingly recognized as import-
ant players in intestinal permeability. The balance be-
tween beneficial and pathogenic bacteria plays a
central role in the mucosal immune response in IBD.
We investigated whether BS treatment changes the
composition of microflora through analysis of feces
(Fig. 4c-e). In this study, we observed that the quan-
tity of bacteria associated with anti-inflammatory re-
sponses, such as Bacteroides spp., Faecalibacterium
prausnitzii, and Lactobacillus spp., was diminished in
fecal samples from the DSS-treated group compared
with control group. Although contents of Bacteroides
and Faecalibacterium prausnitzii spp. did not change,
BS treatment prevented the decrease of Lactobacillus
spp., suggesting that BS might contribute to the
Fig. 2 BS attenuated the progression of DSS-induced colitis. a Mice body weight was measured every other day for evaluation of BS efficacy on
DSS-induced colitis, and was shown as percentage of weight change. b DAI and (c) colon length were evaluated. d Representative H&E stained
histology from vehicle, 5% DSS, and BS-treated groups. Magnification: ×100 (upper), ×200 (lower) (e) Expression of pro-inflammatory cytokines in
colon was assessed by semi-quantitative RT-PCR. Statistically differences were analyzed with one-way ANOVA. The data are presented as mean ±
SD of triplicate experiments. *p < 0.05 and **p < 0.01 vs 5% DSS-treated group
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improvement of gut immune and barrier function by
altering intestinal microbiota, which play a significant
role in anti-inflammation.
Discussion
Although some medicines such as 5-aminosalicylic acid
have been developed to treat IBD, they are not effective
enough to cure it. Moreover, most of the drugs currently
used to treat IBD have untoward effects. Therefore,
there is a growing need to develop efficient and safe
treatments for IBD. Consequently, traditional medicinal
plants, herb, vegetables and their secondary metabolites
are considered to be alternative treatment strategies for
IBD [16].
Many studies have reported that various food supple-
ments provide many beneficial effects in the gut. β-
glucan, produced by barley and oat, is known to have
anti-inflammatory properties [17]. Dietary β-glucan is
also effective to treat IBD [18, 19]. Genistein and daid-
zein, the active isoflavonoids mainly found in soybean,
are also known to have anti-inflammatory effects in a
colitis-induced mouse model [20, 21]. In addition,
genistein has protective effects on intestinal barrier func-
tion by regulating tight junction [22]. Although these
natural products contain many beneficial bioactive sub-
stances, there are some limits in terms of efficacy. Sev-
eral studies have demonstrated that fermentation of the
natural products improved biological activities [23].
Therefore, in order to enhance the beneficial effects of
soybean and barley, we increased the activity of β-
glucans, daidzein and genistein in barley and soybean by
yeast fermentation.
Recently, experimental and clinical studies suggest that
disruption and reassembly of tight junction is an import-
ant determinant of IBD [24, 25]. Our data show that BS
treatment prevents DSS-induced redistribution or loss of
tight junction proteins like ZO-1, Occludin, and
Claudin-1 in Caco-2 monolayer.
To elucidate the anti-colitis potency of BS in IBD,
we used a DSS-induced colitis model. Our findings
show that BS suppresses symptoms of DSS-induced
colitis such as body weight loss, colon length shorten-
ing, bloody feces and stool consistency. BS treatment
also reduced the DSS-induced expression of anti-
Fig. 3 Effect of BS on colonic epithelial tight junctions proteins. a Expression of ZO-1, Occludin and Claudin-1 was examined by immunostaining
using anti-zo-1 (green), anti-Occludin (green), and anti-Claudin-1 (green) antibodies in vehicle, DSS, and BS-treated groups. Magnification:
×600. b Expression of TJ proteins in the colon was assessed by Western blot
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inflammatory cytokines such as TNF-α, IL-1β, IL-6,
IL-12p40. The reduction in pro-inflammatory
cytokines by BS may either be due to its direct sup-
pressive effect on the expression of these pro-
inflammatory cytokines or the indirect effect on
epithelial barrier function. Once the epithelial barrier
is damaged, foreign luminal antigenic products are
able to cross the epithelial barrier and activate the
immune system. Therefore, in addition to anti-
inflammatory effects, we investigated the effect of BS
on epithelial barrier function in DSS-induced colitis.
Consistent with the in vitro experiment, we showed
that BS administration recovered expression or distri-
bution of tight junction proteins, ZO-1, Occludin, and
Claudin-1, in DSS-induced colitis. Furthermore, BS
reduced epithelial barrier permeability in DSS-induced
colitis, as demonstrated by suppression of FITC-D up-
take and bacterial translocation into MLN. Our data
showed that BS might have a protective effect on bar-
rier integrity by maintaining the expression of tight
junction proteins, thereby reducing the severity of
colitis.
Accumulating evidence indicates that commensal bac-
teria are responsible for various physiological functions
and are associated with immune-enhancing effects in
the gut [26]. Several studies have suggested a critical role
of microbial imbalances in the pathogenesis of IBD [27].
In IBD patients, the quantity of commensal bacteria in
the intestine is reduced, and the diversity of the
microbiota is also altered [1]. It was reported that
Bacterioidetes, Lactobacillus spp. and Faecalibacterium
prausnitzii are reduced in IBD patients [28]. Therefore,
we analyzed the change of intestinal bacteria compos-
ition by using fecal DNA. We observed that Lactobacil-
lus spp. was reduced in DSS-treated group, but BS
administration prevented alteration of the bacterial
composition.
Conclusions
In summary, our data suggest that BS is effective for the
amelioration of DSS-induced acute colitis, recovering
epithelial barrier function and regulating the gut micro-
biota community.
Fig. 4 BS suppressed epithelial permeability and increased microbiota quantity in DSS-induced colitis model. a colony number of viable bacteria
in MLNs, (b) Relative level of serum FITC-D, (c-e) fecal microbiota composition were shown in vehicle, DSS, and BS-treated groups; (c) Lactobacilli,
(d) Faecalibacterium prausnitzii, and (e) Bacteroides. Statistically differences were analyzed with one-way ANOVA. The data are presented as mean
± SD of triplicate experiments. *p < 0.05 and ***p < 0.01 vs 5% DSS treated group
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Additional files
Additional file 1: Table S1. Primer sets used for semi-quantitative PCR
of cytokines. Table S2. Primer sets used for quantitative PCR of 16S
rRNAof specific species or genus. (PDF 105 kb)
Additional file 2: Figure S1. BS promotes recovery from LPS-induced
colitis and inflammation in mice. (A) DAI of LPS (LPS, 5 mg/kg of mouse
by Intra-peritoneal injection) treated mice were scored. (B) Representative
H&E stained histology from Control and BS-treated groups and statistical
results. Mean value was significantly different from that of the LPS treated
control group (*P < 0.05). BS, Fermented barley and soybean, DAI, disease
activity index. LPS, Lipopolysaccharide. Figure S2. Basal intestinal barrier
function in BS treatment. (A) Immunofluorescence of ZO-1 in Caco-2 cell
monolayers incubated with BS for 48 h and images were collected by
confocal microscopy. (B) RNA levels of ZO-1, Claudin1, and Occludinin BS
treated Caco-2 cells measured by semi-quantitative RT-PCR. (C) BS treated
mouse colon tissues were used to determine ZO-1, Claudin1 and
Occludindistribution by immune fluorescence staining and images
were collected by confocal microscopy. BS, Fermented barley and
soybean. Figure S3. Effect of BS on the suppression of NF-κBactivity.
(A) Western blot analysis of p65 nuclear trans-localization levels in
the protein fractions of RAW 264.7 lysates. (B) The effects of BS on a
NF-κBreporter assay in HEK 293 cells that were activated by the
addition of LPS. The luciferase activity was measured as relative light
intensity, using a plate reader in the luminescence mode. BS,
Fermented barley and soybean, LPS, Lipopolysaccharide. Figure S4.
Immunohistochemicalstaining of IL-6 in sections from BS treated
mouse colon. BS, Fermented barley and soybean. (PDF 563 kb)
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